keyword
MENU ▼
Read by QxMD icon Read
search

EULAR recommendations

keyword
https://www.readbyqxmd.com/read/29165607/an-evidence-based-approach-to-pre-pregnancy-counselling-for-patients-with-systemic-lupus-erythematosus
#1
Y K Onno Teng, Edwin O W Bredewold, Ton J Rabelink, Tom W J Huizinga, H C Jeroen Eikenboom, Maarten Limper, Ruth D E Fritsch-Stork, Kitty W M Bloemenkamp, Marieke Sueters
Patients with SLE are often young females of childbearing age and a pregnancy wish in this patient group is common. However, SLE patients are at high risk for adverse pregnancy outcomes that require adequate guidance. It is widely acknowledged that pre-pregnancy counselling is the pivotal first step in the management of SLE patients with a wish to become pregnant. Next, management of these patients is usually multidisciplinary and often requires specific expertise from the different physicians involved. Very recently a EULAR recommendation was published emphasizing the need for adequate preconception counselling and risk stratification...
November 20, 2017: Rheumatology
https://www.readbyqxmd.com/read/29155104/treatment-strategies-for-psoriatic-arthritis
#2
Julien Schemoul, Cécile Poulain, Pascal Claudepierre
The therapeutic management of psoriatic arthritis has seen major changes over the last few years, as illustrated by the recent updates of the GRAPPA and EULAR recommendations. These changes were driven by new studies establishing important benefits from early management and tight control of disease activity. The concepts underlying the treatment of psoriatic arthritis must be reappraised in the light of these new data. The objectives of this review are to discuss new concepts, to describe and assess the new drug classes introduced for psoriatic arthritis and, whenever possible, to define the specific indications of each class based on the rheumatic disease phenotype and presence of extraarticular manifestations...
November 16, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29142027/underestimation-of-risk-of-carotid-subclinical-atherosclerosis-by-cardiovascular-risk-scores-in-patients-with-psoriatic-arthritis
#3
Jiayun Shen, Steven H Lam, Qing Shang, Chun-Kwok Wong, Edmund K Li, Priscilla Wong, Emily W Kun, Isaac T Cheng, Martin Li, Tena K Li, Tracy Y Zhu, Jack Jock-Wai Lee, Mimi Chang, Alex Pui-Wai Lee, Lai-Shan Tam
OBJECTIVE: To test the performances of established cardiovascular (CV) risk scores in discriminating subclinical atherosclerosis (SCA) in patients with psoriatic arthritis. METHODS: These scores were calculated: Framingham risk score (FRS), QRISK2, Systematic COronary Risk Evaluation (SCORE), 10-year atherosclerotic cardiovascular disease risk algorithm (ASCVD) from the American College of Cardiology and the American Heart Association, and the European League Against Rheumatism (EULAR)-recommended modified versions (by 1...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29132341/can-hybrid-hyaluronic-acid-represent-a-valid-approach-to-treat-rizoarthrosis-a-retrospective-comparative-study
#4
Sara Tenti, Nicola Antonio Pascarelli, Stefano Giannotti, Mauro Galeazzi, Nicola Giordano, Antonella Fioravanti
BACKGROUND: Osteoarthritis (OA) of the trapeziometacarpal joint (TMJ) is a disabling condition with a significant impact on quality of life. The optimal management of hand OA requires a combination of non-pharmacological and pharmacological treatments that include intra-articular (i.a.) therapy. EULAR experts recommend corticosteroid injections in TMJ OA and underline the usefulness of hyaluronic acid (HA). The aim of this study was the assessment of the efficacy and tolerability of i...
November 13, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29106061/2017-european-league-against-rheumatism-american-college-of-rheumatology-classification-criteria-for-adult-and-juvenile-idiopathic-inflammatory-myopathies-and-their-major-subgroups
#5
Ingrid E Lundberg, Anna Tjärnlund, Matteo Bottai, Victoria P Werth, Clarissa Pilkington, Marianne de Visser, Lars Alfredsson, Anthony A Amato, Richard J Barohn, Matthew H Liang, Jasvinder A Singh, Rohit Aggarwal, Snjolaug Arnardottir, Hector Chinoy, Robert G Cooper, Katalin Dankó, Mazen M Dimachkie, Brian M Feldman, Ignacio Garcia-De La Torre, Patrick Gordon, Taichi Hayashi, James D Katz, Hitoshi Kohsaka, Peter A Lachenbruch, Bianca A Lang, Yuhui Li, Chester V Oddis, Marzena Olesinska, Ann M Reed, Lidia Rutkowska-Sak, Helga Sanner, Albert Selva-O'Callaghan, Yeong-Wook Song, Jiri Vencovsky, Steven R Ytterberg, Frederick W Miller, Lisa G Rider
OBJECTIVE: To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups. METHODS: Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology, and pediatric clinics worldwide. Several statistical methods were utilized to derive the classification criteria. RESULTS: Based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived...
October 27, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29079590/2017-european-league-against-rheumatism-american-college-of-rheumatology-classification-criteria-for-adult-and-juvenile-idiopathic-inflammatory-myopathies-and-their-major-subgroups
#6
REVIEW
Ingrid E Lundberg, Anna Tjärnlund, Matteo Bottai, Victoria P Werth, Clarissa Pilkington, Marianne de Visser, Lars Alfredsson, Anthony A Amato, Richard J Barohn, Matthew H Liang, Jasvinder A Singh, Rohit Aggarwal, Snjolaug Arnardottir, Hector Chinoy, Robert G Cooper, Katalin Dankó, Mazen M Dimachkie, Brian M Feldman, Ignacio Garcia-De La Torre, Patrick Gordon, Taichi Hayashi, James D Katz, Hitoshi Kohsaka, Peter A Lachenbruch, Bianca A Lang, Yuhui Li, Chester V Oddis, Marzena Olesinska, Ann M Reed, Lidia Rutkowska-Sak, Helga Sanner, Albert Selva-O'Callaghan, Yeong-Wook Song, Jiri Vencovsky, Steven R Ytterberg, Frederick W Miller, Lisa G Rider
OBJECTIVE: To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups. METHODS: Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology and paediatric clinics worldwide. Several statistical methods were used to derive the classification criteria. RESULTS: Based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived...
October 27, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29056777/relapsing-granulomatosis-with-polyangiitis-with-severe-lung-and-upper-respiratory-tract-involvement-successfully-treated-with-rituximab
#7
Anna Masiak, Zbigniew Zdrojewski
Granulomatosis with polyangiitis (GPA) is a chronic, relapsing, primary systemic small vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies. The disease is characterised by the involvement of various organs. The relapse rate rises from about 20% at 12 months to about 60% at 5 years. The combination of glucocorticoids and cyclophosphamide remains the standard therapy for patients with generalised GPA; nevertheless, some patients do not respond satisfactorily to this treatment. According to EULAR-EDTA recommendations for the management of ANCA-associated vasculitis, RTX should be considered for remission-induction of new-onset as well as major relapse of organ-threatening or life-threatening GPA...
2017: Reumatologia
https://www.readbyqxmd.com/read/29056774/glucocorticoid-management-in-rheumatoid-arthritis-morning-or-night-low-dose
#8
REVIEW
Sabrina Paolino, Maurizio Cutolo, Carmen Pizzorni
Morning symptoms of rheumatoid arthritis (RA) are linked to circadian increase of night inflammation, supported by inadequate cortisol secretion in active disease. Therefore, exogenous glucocorticoid administration in RA is recommended by EULAR and ACR from the beginning of the diagnosis, since may partially act like a "replacement therapy". In addition, the prevention/treatment of the night up-regulation of the immune/inflammatory reaction has been shown more effective when exogenous glucocorticoid administration is managed with a night-time-release formulation...
2017: Reumatologia
https://www.readbyqxmd.com/read/28968896/recent-pharmacological-advances-in-the-management-of-gout
#9
Kristen Davies, Marwan A S Bukhari
Gout is the most common cause of inflammatory arthritis worldwide, and reports show that despite availability of therapies, management is still suboptimal. The new EULAR 2016 recommendations for the treatment of gout highlight the huge development in gout therapies, and the number of drugs being trialled only continues to increase. A clinical review of the evidence that underlies the recommendations from EULAR can reveal possible gaps in the literature and avenues for future research into gout therapies.
September 14, 2017: Rheumatology
https://www.readbyqxmd.com/read/28967358/causes-of-pain-in-patients-with-axial-spondyloarthritis
#10
REVIEW
Uta Kiltz, Xenofon Baraliakos, Andrea Regel, Bjoern Bühring, Juergen Braun
Back pain, most frequently of the inflammatory type, is the leading symptom in patients with axial spondyloarthritis (axSpA). Back pain in these patients is usually either due to axial inflammation or structural changes based on new bone formation. However, there are other possible causes of pain in these patients. There is, for example, a strongly increased risk of vertebral fractures, and, especially in patients with longstanding disease, degenerative spinal changes may play an additional role as a cause of pain...
September 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28955487/validation-of-the-eular-era-edta-recommendations-for-the-management-of-anca-associated-vasculitis-by-disease-content-experts
#11
Max Yates, Richard Watts, Ingeborg Bajema, Maria Cid, Bruno Crestani, Thomas Hauser, Bernhard Hellmich, Julia Holle, Martin Laudien, Mark A Little, Raashid Ahmed Luqmani, Alfred Mahr, Peter Merkel, John Mills, Janice Mooney, Mårten Segelmark, Vladimir Tesar, Kerstin W A Westman, Augusto Vaglio, Nilüfer Yalçındağ, David R Jayne, Chetan Mukhtyar
The European League Against Rheumatism recommendations for the management of antineutrophil cytoplasmic antibody-associated vasculitis have been recently published. Unique to recommendation development, they were also voted on by members of a learned society. This paper explores the wider validity of the recommendations among people who self-identify as clinicians caring for patients with vasculitis. In addition to the task force, a learned society (European Vasculitis Society-EUVAS) was invited, through online survey, to rate independently the strength of evidence of each recommendation to obtain an indication of the agreement among the final target audience and ultimate end-users of the recommendations...
2017: RMD Open
https://www.readbyqxmd.com/read/28943233/unravelling-fibromyalgia-steps-toward-individualized-management
#12
Winfried Häuser, Serge Perrot, Daniel J Clauw, Mary-Ann Fitzcharles
The heterogeneity of the clinical presentation and the pathophysiologic mechanisms associated with fibromyalgia (FM), and the modest results on average for any therapy, call for a more individualized management strategy. Individualized treatment can be on the basis of subgrouping of patients according to associated conditions (mental health problems, chronic overlapping pain conditions, other somatic diseases) or on disease severity. Categorizing FM as mild, moderate, or severe can be on the basis of clinical assessment (eg, degree of daily functioning) or on questionnaires...
September 21, 2017: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28895041/unmet-needs-in-the-pathogenesis-and-treatment-of-vasculitides
#13
REVIEW
Francesco Muratore, Giulia Pazzola, Alessandra Soriano, Nicolò Pipitone, Stefania Croci, Martina Bonacini, Luigi Boiardi, Carlo Salvarani
Despite the progress in the last years on the field of vasculitides, there are several unmet needs regarding classification, disease activity assessment, predictors of flares and complications, and type of treatment for the different forms. The 1990 American College of Rheumatology (ACR) classification criteria currently used to define giant cell arteritis and Takayasu arteritis were designed to discriminate between different types of vasculitides but not to differentiate vasculitis from other disorders. Recently, efforts have been made to overcome the shortcomings of the ACR criteria...
September 11, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28891365/gout-in-a-rheumatology-clinic-results-of-eular-acr-guidelines-compliant-treatment
#14
O Slot
OBJECTIVE: Surveys of treatment results of gout in primary care have shown that less than 25% of patients reach the recommended treatment target (serum urate < 0.36 mmol/l). The aim of this study was to measure the results of a specialized European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) guidelines-based treatment of gout in a rheumatology clinic. METHOD: Data from consecutive new crystal-proven gout patients were analysed in a prospective observational study...
September 11, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28866648/consensus-based-recommendations-for-the-use-of-biosimilars-to-treat-rheumatological-diseases
#15
Jonathan Kay, Monika M Schoels, Thomas Dörner, Paul Emery, Tore K Kvien, Josef S Smolen, Ferdinand C Breedveld
The study aimed to develop evidence-based recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases. The task force comprised an expert group of specialists in rheumatology, dermatology and gastroenterology, and pharmacologists, patients and a regulator from ten countries. Four key topics regarding biosimilars were identified through a process of discussion and consensus. Using a Delphi process, specific questions were then formulated to guide a systematic literature review...
September 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28831712/treatment-with-biologicals-in-rheumatoid-arthritis-an-overview
#16
REVIEW
Philipp Rein, Ruediger B Mueller
Management and therapy of rheumatoid arthritis (RA) has been revolutionized by the development and approval of the first biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumor necrosis factor (TNF) α at the end of the last century. Today, numerous efficacious agents with different modes of action are available and achievement of clinical remission or, at least, low disease activity is the target of therapy. Early therapeutic interventions aiming at a defined goal of therapy (treat to target) are supposed to halt inflammation, improving symptoms and signs, and preserving structural integrity of the joints in RA...
December 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28794514/discordant-american-college-of-physicians-and-international-rheumatology-guidelines-for-gout-management-consensus-statement-of-the-gout-hyperuricemia-and-crystal-associated-disease-network-g-can
#17
REVIEW
Nicola Dalbeth, Thomas Bardin, Michael Doherty, Frédéric Lioté, Pascal Richette, Kenneth G Saag, Alexander K So, Lisa K Stamp, Hyon K Choi, Robert Terkeltaub
In November 2016, the American College of Physicians (ACP) published a clinical practice guideline on the management of acute and recurrent gout. This guideline differs substantially from the latest guidelines generated by the American College of Rheumatology (ACR), European League Against Rheumatism (EULAR) and 3e (Evidence, Expertise, Exchange) Initiative, despite reviewing largely the same body of evidence. The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) convened an expert panel to review the methodology and conclusions of these four sets of guidelines and examine possible reasons for discordance between them...
September 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28765712/mean-cost-per-number-needed-to-treat-with-tocilizumab-plus-methotrexate-versus-abatacept-plus-methotrexate-in-the-treatment-of-rheumatoid-arthritis-in-patients-previously-treated-with-methotrexate
#18
Maurizio Benucci, Roberto Ravasio, Arianna Damiani
INTRODUCTION: Biological disease-modifying antirheumatic drugs are particularly recommended for use in patients who are poor responders, are intolerant to conventional disease-modifying antirheumatic drugs (cDMARDs), or in whom continued treatment with cDMARDs is deemed inappropriate. We estimated the efficacy and treatment costs associated with the use of tocilizumab (TCZ) plus methotrexate (Mtx) versus abatacept (ABT) plus Mtx in the treatment of rheumatoid arthritis (RA) in patients previously treated with Mtx...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28740623/patient-access-to-reimbursed-biological-disease-modifying-antirheumatic-drugs-in-the-european-region
#19
Zoltán Kaló, Zoltán Vokó, Andrew Östör, Emma Clifton-Brown, Radu Vasilescu, Alysia Battersby, Edward Gibson
Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted healthcare budgets. This study compares the size of RA patient populations with access to reimbursed bDMARDs across 37 European countries, Russia, and Turkey, according to their treatment eligibility defined by European League Against Rheumatism (EULAR) recommendations and national reimbursement criteria...
2017: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/28704564/poor-clinical-response-in-rheumatoid-arthritis-is-the-main-risk-factor-for-diabetes-development-in-the-short-term-a-1-year-single-centre-longitudinal-study
#20
Piero Ruscitti, Francesco Ursini, Paola Cipriani, Vasiliki Liakouli, Francesco Carubbi, Onorina Berardicurti, Giovambattista De Sarro, Roberto Giacomelli
OBJECTIVES: Despite of the European League Against Rheumatism (EULAR) provided different sets of recommendations for the management of cardiovascular risk in inflammatory arthritis patients, it must be pointed out that cardiometabolic comorbidity, such as type 2 diabetes (T2D), remains still underdiagnosed and undertreated in patients affected by rheumatoid arthritis (RA). METHODS: In this work, we designed a single centre, prospective study in order to better investigate the occurrence of T2D during the course of 1 year of follow-up...
2017: PloS One
keyword
keyword
108134
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"